
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is poised for success as they have achieved solid financial results, with top-line revenue and full-year earnings either meeting or exceeding projected numbers for 2025. They have a strong cash position and a positive outlook with promising clinical trials in the pipeline. Their proprietary technology and recent advancements in non-invasive depression treatment provide a competitive advantage and potential for widespread adoption. However, risks include slower-than-projected uptake, failure to expand reimbursement and market access, inability to advance in other indications, and potential long-term dilution risk.
Bears say
BrainsWay is making strategic investments in complementary businesses, while also receiving FDA approval for their at-home neuromodulation device for treatment resistant depression, which expands their potential market beyond first-generation in-clinic care. This can potentially lead to an increase in forward earnings multiple and an increase in the company's intrinsic value. However, the stock's price may also be affected by future investments and potential acquisition of Neurolief, which could add additional risk.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares